CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy

Journal of Molecular Histology

Volumn 45, Issue 1, 2014, Pages 35-45

  Adamczyk, Agnieszka ^a   Niemiec, Joanna A ^a   Ambicka, Aleksandra ^a   Mucha Małecka, Anna ^a   Mituś, Jerzy ^a   Ryś, Janusz ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Breast cancer; CD24; CD44; Disease free survival; Immunophenotype

Indexed keywords

AROMATASE INHIBITOR; CD24 ANTIGEN; CYTOKERATIN; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FASCIN; GONADORELIN DERIVATIVE; HERMES ANTIGEN; KALININ; KI 67 ANTIGEN; P CADHERIN; PROGESTERONE RECEPTOR; SMOOTH MUSCLE ACTIN; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD24; ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARRIER PROTEINS; CELL ADHESION MOLECULES; CHEMORADIOTHERAPY, ADJUVANT; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84895072895     PISSN: 15672379     EISSN: 15672387     Source Type: Journal    
DOI: 10.1007/s10735-013-9523-6     Document Type: Article

References (47)

1. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H (2005) Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11(3):1154-1159
2. Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18(5):460-466
3. Al-Alwan M, Olabi S, Ghebeh H et al (2011) Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS ONE 6(11):e27339
4. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983-3988
5. Anders CK, Carey LA (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 9(Suppl 2):S73-S81
6. Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A, Patsouris E (2009) CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 205(8):524-533
7. Badve S, Nakshatri H (2012) Breast-cancer stem cells-beyond semantics. Lancet Oncol 13(1):e43-e48
8. Bocker W, Moll R, Poremba C et al (2002) Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. Lab Invest 82(6):737-746
9. Catusse C, Polette M, Coraux C, Burlet H, Birembaut P (2000) Modified basement membrane composition during bronchopulmonary tumor progression. J Histochem Cytochem 48(5):663-669
10. Deng J, Gao G, Wang L, Wang T, Yu J, Zhao Z (2012) CD24 expression as a marker for predicting clinical outcome in human gliomas. J Biomed Biotechnol 517172, doi: 10.1155/2012/517172
11. Dontu G, El-Ashry D, Wicha MS (2004) Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 15(5):193-197
12. Fountzilas G, Dafni U, Bobos M et al (2012) Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS ONE 7(6):e37946
13. Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer. Ann Oncol 18(7):1133-1144
14. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736-1747
15. Grothey A, Hashizume R, Sahin AA, McCrea PD (2000) Fascin, an actin-bundling protein associated with cell motility, is upregulated in hormone receptor negative breast cancer. Br J Cancer 83(7):870-873
16. Harris LN, Broadwater G, Lin NU, et al. (2006) Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res 8(6):R66
17. Honeth G, Bendahl PO, Ringnér M et al (2008) The CD44 +/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10(3):R53
18. Horiguchi K, Toi M, Horiguchi S et al (2010) Predictive value of CD24 and CD44 for neoadjuvant chemotherapy response and prognosis in primary breast cancer patients. J Med Dent Sci 57(2):165-175
19. Hugh J, Hanson J, Cheang MC, Nielsen TO, Perou CM, Dumontet C, Reed J, Krajewska M, Treilleux I, Rupin M, Magherini E, Mackey J, Martin M, Vogel C (2009) Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 27(8):1168-1176
20. Idowu MO, Kmieciak M, Dumur C et al (2012) CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43(3):364-373
21. Jaggupilli A, Elkord E (2012) Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol doi: 10.1155/2012/708036
22. Jia Z, Zhao W, Fan L, Sheng W (2012) The expression of PCNA, c-erbB-2, p53, ER and PR as well as atypical hyperplasia in tissues nearby the breast cancer. J Mol Histol 43(1):115-120
23. Kim HJ, Kim MJ, Ahn SH et al (2011) Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 20(1):78-85
24. Konecny GE, Pauletti G, Untch M et al (2010) Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat 120(2):481-489
25. Kristiansen G, Sammar M, Altevogt P (2004) Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35(3):255-262
26. Kwon GY, Ha H, Ahn G, Park SY, Huh SJ, Park W (2007) Role of CD24 protein in predicting metastatic potential of uterine cervical squamous cell carcinoma in patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 69(4):1150-1156
27. Lim SC (2005) CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 59(Suppl 2):S351-S354
28. Lim SC, Oh SH (2005) The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 201(7):479-486
29. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374
30. Niemiec J, Adamczyk A, Małecki K, Ambicka A, Ryś J (2013) Tumor grade and matrix metalloproteinase 2 expression in stromal fibroblasts help to stratify the high-risk group of patients with early breast cancer identified on the basis of St Gallen recommendations. Clin Breast Cancer 13(2):119-128
31. Oliveira LR, Jeffrey SS, Ribeiro-Silva A (2010) Stem cells in human breast cancer. Histol Histopathol 25(3):371-385
32. Paredes J, Lopes N, Milanezi F et al (2007) P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ. Virchows Arch 450:73-80
33. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K (2010) Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16(3):876-887
34. Rakha EA, Putti TC, Abd El-Rehim DM et al (2006) Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 208(4):495-506
35. Ricardo S, Vieira AF, Gerhard R et al (2011) Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol 64(11):937-946
36. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12(5):1533-1539
37. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-5685
38. Skyldberg B, Salo S, Eriksson E et al (1999) Laminin-5 as a marker of invasiveness in cervical lesions. J Natl Cancer Inst 91(21):1882-1887
39. Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418-8423
40. Sung JY, Kim GY, Park YK, Lee J, Kim YW, Lim SJ (2010) Clinicopathological significance of invasive ductal carcinoma with high prevalence of CD44+/CD24-/low tumor cells in breast cancer. Korean J Pathol 44(4):390-396
41. Surowiak P, Materna V, Györffy B et al (2006) Multivariate analysis of oestrogen receptor alpha, pS2, metallothionein and CD24 expression in invasive breast cancers. Br J Cancer 95(3):339-346
42. Tanei T, Morimoto K, Shimazu K et al (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res 15(12):4234-4241
43. Thike AA, Iqbal J, Cheok PY et al (2010) Triple negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 34(7):956-964
44. Tischkowitz M, Brunet JS, Be'gin LR et al (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7:134-145
45. Wang Z, Shi Q, Wang Z et al (2011) Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 207(8):505-513
46. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145
47. Yoder BJ, Tso E, Skacel M et al (2005) The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical course. Clin Cancer Res 11(1):186-192